"March 7, 2013 -- An FDA panel voted to stop recommending calcitonin salmon for the treatment of osteoporosis in women who are at least five years past menopause.
The committee voted 12-9 against continued marketing of the drug, citing"...
No cases of overdose were reported in premarketing studies with BONIVA Injection. Overdosage with intravenous bisphosphonates may result in hypocalcemia, hypophosphatemia, and hypomagnesemia. Clinically relevant reductions in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate, respectively.
Dialysis would not be beneficial unless it is administered within 2 hours following the overdose.
Boniva is contraindicated in patients with the following conditions:
- Hypocalcemia [see WARNINGS AND PRECAUTIONS]
- Known hypersensitivity to BONIVA Injection or to any of its excipients. Cases of anaphylaxis, including fatal events, have been reported. [see WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS]
Last reviewed on RxList: 4/7/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Boniva Injection Information
Boniva Injection - User Reviews
Boniva Injection User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips and advances in treatment.